Dermalax Plus — Monophasic HA Filler for Superficial Lines (1.1ml)

Dermalax Plus is Across Co.’s lightest variant — 24 mg/mL monophasic cross-linked HA + 0.3% lidocaine with the smallest particle size in the Dermalax Plus series. Engineered for upper dermal placement targeting thin superficial lines, periorbital wrinkles, and perioral fine lines. CE marked, BDDE residue undetectable, endotoxin under 0.10 EU/mL.

Dermalax Plus Injectable Filler is manufactured by Across Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2007. The product is part of the Dermalax dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE marked · GMP certified.

Dermalax Plus Injectable Filler contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Across Co. Ltd.’s Monophasic Cross-Linked HA (Plus Series) technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Across Co. Ltd.’s clinical data, Dermalax Plus Injectable Filler delivers 6–12 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Upper dermis (superficial) placement typically delivers the longer end of the duration range.

Dermalax Plus Injectable Filler is engineered for upper dermis (superficial) placement. The standard recommended needle is 30G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Dermalax Plus Injectable Filler regulatory status: KFDA registered · CE marked · GMP certified. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Dermalax Plus Injectable Filler between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Dermalax Plus Injectable Filler uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Dermalax Plus Injectable Filler can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

All three are monophasic cross-linked HA fillers from Across Co. with 24 mg/mL HA + 0.3% lidocaine, differing in particle size and intended injection depth. Dermalax Plus has the smallest particles for upper dermal superficial line correction. Dermalax Deep Plus has medium particles for mid-to-deep dermal placement (moderate wrinkles). Dermalax Implant Plus has the largest particles for deep subcutaneous placement (cheek, chin, jawline augmentation). Practitioners select based on the target tissue layer.